Scandinavian ChemoTech updates on its most important milestone

The Company's focus on Human Care in the Indian market is proving to be successful. Our unique TSE technology aligns seamlessly with the healthcare landscape in India, addressing the significant challenges posed by head and neck cancer, which contributes to numerous fatalities and considerable suffering.

While head and neck cancer pose a significant global challenge, India stands out as the country with the highest incidence and mortality rates (recording 200,000 new cases annually[1]).

In October 2022, the clinical trial commenced at Jodhpur University Hospital in India. The trial's objective is to provide clinical evidence supporting the integration of TSE into the standard treatment protocol for head and neck cancer patients as part of the country's national healthcare program.

In our role as a technology partner for the university hospital's innovation centre, ChemoTech has already implemented the initial IQwave™ system ahead of the official study commencement. This pre-installation was conducted to train the team in TSE treatment techniques. The hospital is currently in the process of compiling a case study report detailing the outcomes of the initial treatments.

As per the official study protocol, 9 out of the total 30 patients have undergone treatment. The investigators have submitted a request to modify the inclusion criteria, advocating for the incorporation of TSE at an earlier stage. If approved, this modification would significantly expand the pool of eligible patients. Consequently, doctors would be empowered to administer TSE treatment with curative intent, particularly for cases where the tumour recurs after a surgical procedure. There is optimism that the ethics committee, in its upcoming meeting, will approve the revised protocol. This approval would mark the biggest milestone toward achieving our goal of establishing TSE as a curative treatment method, thereby enhancing the Company's global potential.

The intention is to commence treatment for the initial patients under the revised protocol in the first or second quarter of 2024.

Here are some remarks from Dr. Suhail Mufti, CMD at ChemoTech, concerning the potential approval of the new protocol:

"I am filled with optimism that the approval of the amended protocol will mark the beginning of a groundbreaking era, allowing TSE to unfold it´s true potential in curative therapies—a crucial advancement addressing a major clinical need. This pioneering approach, both biologically and scientifically plausible, signifies a historic milestone, as neither ablation nor electroporation technologies have been previously considered in trials of earlier lines of therapy for Head and Neck tumours."

“The fact that our TSE therapy is currently being evaluated for its curative potential in a clinical trial at one of the leading University hospitals in India represents a crucial milestone in ChemoTech's history. As the co-innovator of TSE, this development fills me with immense pride.” - says Mohan Frick CEO and Co-Founder of ChemoTech.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.